The University of Washington Division of Rheumatology is committed to supporting biomedical research endeavors to improve rheumatic and autoimmune disease outcomes. Led by Dr. Bobby Han, we partner with practicing physicians and industry sponsors to conduct health-related interventional and observational studies.

If you would like more information on any of our studies, please contact us at (206) 616-5330 or

Currently Enrolling

Disease Indication Study Information
Systemic Lupus Erythematosus

IM011-021: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

CNTO1275SLE3001: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus

  • Investigator: Bobby Han, MD
  • Study Coordinator: Jennifer Schaeffer, CCRC
Rheumatoid Arthritis

STUDY00004744: Phase IV Open-Label Study to Evaluate Biomarkers to Predict the Efficacy of Abatacept in Subjects with Rheumatoid Arthritis

Ankylosing Spondylitis

CAIN457FUS06: A randomized, double-blind, parallel-group, multicenter study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with Ankylosing Spondylitis who are randomized to dose escalation after not achieving inactive disease during an initial 16 weeks of open-label treatment with secukinumab 150 mg (ASLeap)

Idiopathic Inflammatory Myopathy

IM101-611A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults with Active Idiopathic Inflammatory Myopathy (IIM)

Systemic Lupus Erythematosus or Healthy Adults

HSD50655: Photoprovocation Testing in Subjects with Systemic Lupus Erythematosus

Open to All

STUDY00003007: Rheumatic Disease Biorepository & Patient Registry


Upcoming Study Areas

Stay tuned for more information on upcoming studies for Systemic Lupus Erythematosus, Rheumatoid Arthritis, Giant Cell Arteritis, Lupus Nephritis, and Scleroderma.

Contact Us

Connect with the team via email or call to speak with our Research Manager.


Phone: 206-616-5330

If you have questions, are interested in participating, or want to sponsor a study at our site, let us know!